Sensorion Reports Results from the P-IIa Trial of SENS-401 for Residual Hearing Preservation after Cochlear Implantation
Shots:
- The P-IIa study assesses SENS-401’s presence in the cochlea post 7 days treatment (BID, oral) before cochlear implantation in patients with moderately severe to profound hearing impairment. Total 28 patients were randomized while 25 patients received cochlear implant (16 in treated arm, 9 in control nontreated arm)
- The study met the 1EP showing SENS-401’s presence in 100% of patient’s cochlea at a level compatible with therapeutic efficacy confirming its ability to cross the labyrinth barrier. Last patient follow-up is underway & 2EPs will be analyzed later in 2024. Full study results are anticipated in Q3'24
- SENS-401 is a small molecule developed to protect inner ear tissue & prevent progressive or sequelae hearing impairment
Ref: Sensorion | Image: Sensorion
Related News:- Sensorion Concludes Patient Enrolment in the P-IIa Study of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
